iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide The FDA has approved the first pill version of GLP-1 drugs. Novo Nordisk says participants who took the Wegovy pill in clinical trials lost an average of 16.6% of their body Outlook for obesity in 2025:

You should not use tirzepatide if you or a family member has a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

The most accurate way to measure visceral fat is with imaging scans such as CT or MRI

Hence pharma needs new value capture points before generics arrive

Novo Nordisk spent $7.6 million lobbying Congress over the past 12 months, and lobbying disclosures show that most of that was to promote bills in the House and Senate to expand use of the GLP-1 drugs

So even the minimum therapeutic tirzepatide dose of 5 mg exceeds the maximum approved semaglutide dose

JCI Insight 6(22):e153732